Medical News Today: What to know about amlodipine
Doctors mainly prescribe amlodipine (Norvasc) to treat people with high blood pressure, coronary artery disease, and angina. It is generally a safe and effective drug, but it may cause side effects in some people. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 24, 2019 Category: Consumer Health News Tags: Pharmacy / Pharmacist Source Type: news
Zydus receives final approvals from USFDA for skin ointment, heart medicine
The group also received a final nod for Amlodipine and Atorvastatin Tablets USP that is administered for heart and cholesterol-related cases. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 12, 2019 Category: Pharmaceuticals Source Type: news
Heart Drug Recall Expanded Again
(CNN) — The recall of popular heart drugs has expanded yet again.
The US Food and Drug Administration said Thursday that Torrent Pharmaceuticals has added eight additional lots of losartan potassium tablets to its recall list. Losartan potassium is a drug used to control high blood pressure. It is also used to treat kidney disease in patients with diabetes.
This recall includes 30-, 90- and 1,000-count bottles of 100-milligram tablets; 30-, 90- and 1,000-count bottles of 50-milligram tablets; and 90-count bottles of 25-milligram tablets. Torrent is recalling only these particular losartan potassium tablets. Tests fou...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 4, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Recall Valsartan Source Type: news
Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 80 Lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP, Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity
Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. To date, Aurob...
Source: Food and Drug Administration - January 1, 2019 Category: Food Science Source Type: news
Mylan Expands Recall to All Unexpired Lots of Valsartan in US Mylan Expands Recall to All Unexpired Lots of Valsartan in US
The latest recall stems from NDEA contamination and includes 26 lots of amlodipine/valsartan tablets, 51 lots of valsartan tablets, and 27 lots of valsartan/hydrochlorothiazide tablets.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 6, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news
Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient
– Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochlorothiazide Tablets, USP (80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg strengths). (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 4, 2018 Category: Food Science Source Type: news
Teva Recalls Two Blood Pressure Medications
FRIDAY, Nov. 30, 2018 -- All lots of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide combination blood pressure tablets have been recalled by Teva Pharmaceuticals due to higher-than-acceptable levels of a chemical that may cause... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 30, 2018 Category: Pharmaceuticals Source Type: news
Teva Recalls All Amlodipine/Valsartan Combination Products in US Teva Recalls All Amlodipine/Valsartan Combination Products in US
In the ongoing saga of tainted sartans, Teva recalls all amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide combination products because of contamination with NDEA.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news
Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets That Are Within Expiry
Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine / Valsartan combination tablets and Amlodipine / Valsartan / Hydrochlorothiazide combination tablets (see table below) due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India.
The impurity found in Mylan ’s valsartan API is known as N-nitroso-diethylamine (NDEA), which has been classified as a probable human carcinogen. This chemical is typically found in very small amounts in certain foods, drinking water, air pollution, and c...
Source: Food and Drug Administration - November 27, 2018 Category: Food Science Source Type: news
Mylan Recalls 15 Lots of Valsartan Products in US Mylan Recalls 15 Lots of Valsartan Products in US
The Mylan recall of valsartan tablets, amlodipine/valsartan tablets, and valsartan/hydrochlorothiazide tablets marks the latest recall of sartans contaminated with probable carcinogens.News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 21, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news
Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient
Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall to the consumer level of select lots of Valsartan-containing products, including six lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, and 10mg/320mg strengths), seven lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths), and two lots of Valsartan and Hydrochlorothiazide Tablets, USP 320mg/25mg strength. These products are being recalled due to detected trace amounts of an impurity, N-nitrosodiethylamine (NDEA) contained in...
Source: Food and Drug Administration - November 21, 2018 Category: Food Science Source Type: news
UPDATED:ADDITIONAL LOTS ADDED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets
Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer ...
Source: Food and Drug Administration - August 22, 2018 Category: Food Science Source Type: news
UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets
Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer ...
Source: Food and Drug Administration - August 22, 2018 Category: Food Science Source Type: news
Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan / Amlodipine / HCTZ Tablets
Torrent Pharmaceuticals Limited is voluntarily recalling 14 lots of Valsartan/Amlodipine/HCTZ tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 18, 2018 Category: Food Science Source Type: news
Concensi (Amlodipine and Celecoxib Tablet) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 8, 2018 Category: Drugs & Pharmacology Source Type: news
